Pharmacological characterization of SAGE-718, a novel NMDA receptor positive allosteric modulator.

Jacob T BeckleyTeresa K AmanMichael A AckleyTatiana M KazdobaMichael C LewisAnne C SmithBrandon J FarleyJing DaiWayne DeatsEthan HoffmannAlbert J RobichaudJames J DohertyMichael C Quirk

Published in: British journal of pharmacology (2023)

These findings provide strong evidence that SAGE-718 is a NAS NMDAR PAM with a mechanism that is well suited as a treatment for conditions associated with NMDAR hypofunction.

Keyphrases

small molecule
smoking cessation